Deciphera Pharmaceuticals $172.5 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers in connection with a $172.5 million SEC-registered common stock and pre-funded warrants offering by Deciphera Pharmaceuticals, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “DCPH.”
Based in Waltham, Massachusetts, Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer.
The Davis Polk corporate team included partner Richard D. Truesdell, Jr. and associates Yoojin Nairn-Kim, Xi (Brooke) Zheng and ChengJun Koh. The tax team included partner Mario J. Verdolini and associate Ben Levenback. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. The environmental team included counsel Loyti Cheng and associate Timothy J. Sullivan. All members of the Davis Polk team are based in the New York office.